Related Experiment Video
Updated: Jun 2, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Novel anticoagulation therapy using apple watch after catheter ablation for atrial fibrillation-Up to AF trial:
Akihiro Sunaga1, Nobuaki Tanaka2, Yasuyuki Egami3
1Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Osaka Japan.
Insights
This study tests personalized anticoagulation for atrial fibrillation (AF) using Apple Watch monitoring. It aims to reduce direct oral anticoagulant (DOAC) use by tailoring treatment to detected AF episodes, lowering bleeding risks.
Area of Science:
- Cardiology
- Digital Health
- Personalized Medicine
Background:
- Current guidelines recommend continuous anticoagulation for atrial fibrillation (AF) based on risk scores, which may not account for individual AF episodes.
- This approach can lead to unnecessary bleeding risks in patients who do not have frequent or significant AF episodes.
Purpose of the Study:
- To evaluate the efficacy and safety of personalized anticoagulation therapy guided by Apple Watch for detecting atrial fibrillation (AF).
- To assess the reduction in direct oral anticoagulant (DOAC) usage by tailoring therapy to real-time AF detection.
Main Methods:
- A multicenter prospective single-arm study enrolling 50 patients with a history of AF post-ablation on DOACs.
- Anticoagulation was discontinued if no AF was detected for 30 days, and resumed upon confirmed AF detection.
- Primary endpoint: reduction in DOAC days from day 31 to 360; secondary endpoints: mortality, stroke, thromboembolism, bleeding, and device malfunctions.
Main Results:
- Patient enrollment of 50 participants was completed in April 2024.
- Full follow-up is expected by April 2025, with primary results anticipated in late 2025.
Conclusions:
- The Up to AF trial is pioneering the evaluation of Apple Watch-guided personalized anticoagulation for AF management.
- This approach holds potential for advancing personalized medicine in AF treatment by optimizing anticoagulation strategies.
Background:
Continuous anticoagulation based on the CHA2DS2-VASc score is recommended to prevent embolism caused by atrial fibrillation (AF), but it does not consider AF episodes. The Apple Watch's continuous heart rhythm monitoring and fast-acting direct oral anticoagulants (DOACs) could enable precise, episode-tailored anticoagulation, reducing bleeding risks while preventing stroke. This study evaluates Apple Watch-guided personalized anticoagulation therapy, adjusting DOAC usage based on real-time AF detection.
Methods:
This multicenter prospective single-arm study will enroll patients who have maintained sinus rhythm post-ablation and are on DOACs. The target enrollment is 50 patients free of AF for at least 30 days following the initiation of Apple Watch monitoring. If no AF occurs for the first 30 days of monitoring, anticoagulants will be discontinued on day 31. If AF is confirmed after day 31, DOAC administration will be resumed and continued until the end of the observation period. The primary endpoint is the reduction in the total number of days with DOACs from day 31 to day 360 compared to the conventional method of continuing anticoagulation. Secondary endpoints include all-cause mortality, stroke, systemic thromboembolism, bleeding events, and Apple Watch malfunctions.
Results:
Enrollment of a total of 50 patients was completed in April 2024. Follow-up of the last enrolled patient will be completed in April 2025 and primary results are expected to be available in late 2025.
Conclusions:
The Up to AF trial is the first trial to evaluate Apple Watch-guided personalized anticoagulation therapy. This trial represents a potential advancement in personalized medicine for AF management.
